These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24900213)

  • 61. Structure-activity relationship of triaryl propionic acid analogues on the human EP3 prostanoid receptor.
    Gallant M; Belley M; Carrière MC; Chateauneuf A; Denis D; Lachance N; Lamontagne S; Metters KM; Sawyer N; Slipetz D; Truchon JF; Labelle M
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3813-6. PubMed ID: 14552786
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel 6-aryl-1,4-dihydrobenzo[d]oxazine-2-thiones as potent, selective, and orally active nonsteroidal progesterone receptor agonists.
    Zhang P; Terefenko EA; Fensome A; Wrobel J; Winneker R; Zhang Z
    Bioorg Med Chem Lett; 2003 Apr; 13(7):1313-6. PubMed ID: 12657271
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.
    Hoveyda HR; Roy MO; Blanc S; Noël S; Salvino JM; Ator MA; Fraser G
    Bioorg Med Chem Lett; 2011 Apr; 21(7):1991-6. PubMed ID: 21376585
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A
    Basu S; Barawkar DA; Thorat S; Shejul YD; Patel M; Naykodi M; Jain V; Salve Y; Prasad V; Chaudhary S; Ghosh I; Bhat G; Quraishi A; Patil H; Ansari S; Menon S; Unadkat V; Thakare R; Seervi MS; Meru AV; De S; Bhamidipati RK; Rouduri SR; Palle VP; Chug A; Mookhtiar KA
    J Med Chem; 2017 Jan; 60(2):681-694. PubMed ID: 28055204
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor.
    Juteau H; Gareau Y; Labelle M; Sturino CF; Sawyer N; Tremblay N; Lamontagne S; Carrière MC; Denis D; Metters KM
    Bioorg Med Chem; 2001 Aug; 9(8):1977-84. PubMed ID: 11504634
    [TBL] [Abstract][Full Text] [Related]  

  • 66. SC-46275: a potent and highly selective agonist at the EP3 receptor.
    Savage MA; Moummi C; Karabatsos PJ; Lanthorn TH
    Prostaglandins Leukot Essent Fatty Acids; 1993 Dec; 49(6):939-43. PubMed ID: 8140121
    [TBL] [Abstract][Full Text] [Related]  

  • 67. 3-(2-Aminocarbonylphenyl)propanoic acid analogs as potent and selective EP3 receptor antagonists. Part 3: Synthesis, metabolic stability, and biological evaluation of optically active analogs.
    Asada M; Obitsu T; Kinoshita A; Nagase T; Yoshida T; Yamaura Y; Takizawa H; Yoshikawa K; Sato K; Narita M; Nakai H; Toda M; Tobe Y
    Bioorg Med Chem; 2010 May; 18(9):3212-23. PubMed ID: 20385498
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Discovery of a new class of potent, selective, and orally bioavailable CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.
    Crosignani S; Page P; Missotten M; Colovray V; Cleva C; Arrighi JF; Atherall J; Macritchie J; Martin T; Humbert Y; Gaudet M; Pupowicz D; Maio M; Pittet PA; Golzio L; Giachetti C; Rocha C; Bernardinelli G; Filinchuk Y; Scheer A; Schwarz MK; Chollet A
    J Med Chem; 2008 Apr; 51(7):2227-43. PubMed ID: 18318469
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice.
    McCafferty GP; Misajet BA; Laping NJ; Edwards RM; Thorneloe KS
    Am J Physiol Renal Physiol; 2008 Aug; 295(2):F507-14. PubMed ID: 18508878
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.
    Caroff E; Meyer E; Treiber A; Hilpert K; Riederer MA
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4323-31. PubMed ID: 25113932
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists.
    Fujimoto T; Kunitomo J; Tomata Y; Nishiyama K; Nakashima M; Hirozane M; Yoshikubo S; Hirai K; Marui S
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6414-6. PubMed ID: 21917455
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discovery of novel and long acting muscarinic acetylcholine receptor antagonists.
    Jin J; Wang Y; Shi D; Wang F; Davis RS; Jin Q; Fu W; Foley JJ; Webb EF; Dehaas CJ; Berlanga M; Burman M; Sarau HM; Morrow DM; Rao P; Kallal LA; Moore ML; Rivero RA; Palovich M; Salmon M; Belmonte KE; Busch-Petersen J
    J Med Chem; 2008 Aug; 51(16):4866-9. PubMed ID: 18680280
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.
    Martin RE; Aebi JD; Hornsperger B; Krebs HJ; Kuhn B; Kuglstatter A; Alker AM; Märki HP; Müller S; Burger D; Ottaviani G; Riboulet W; Verry P; Tan X; Amrein K; Mayweg AV
    J Med Chem; 2015 Oct; 58(20):8054-65. PubMed ID: 26403853
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.
    Firooznia F; Cheung AW; Brinkman J; Grimsby J; Gubler ML; Hamid R; Marcopulos N; Ramsey G; Tan J; Wen Y; Sarabu R
    Bioorg Med Chem Lett; 2011 Apr; 21(7):1933-6. PubMed ID: 21388809
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.
    Cho YS; Angove H; Brain C; Chen CH; Cheng H; Cheng R; Chopra R; Chung K; Congreve M; Dagostin C; Davis DJ; Feltell R; Giraldes J; Hiscock SD; Kim S; Kovats S; Lagu B; Lewry K; Loo A; Lu Y; Luzzio M; Maniara W; McMenamin R; Mortenson PN; Benning R; O'Reilly M; Rees DC; Shen J; Smith T; Wang Y; Williams G; Woolford AJ; Wrona W; Xu M; Yang F; Howard S
    ACS Med Chem Lett; 2012 Jun; 3(6):445-9. PubMed ID: 24900493
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
    Duplantier AJ; Dombroski MA; Subramanyam C; Beaulieu AM; Chang SP; Gabel CA; Jordan C; Kalgutkar AS; Kraus KG; Labasi JM; Mussari C; Perregaux DG; Shepard R; Taylor TJ; Trevena KA; Whitney-Pickett C; Yoon K
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3708-11. PubMed ID: 21565499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.
    Arhancet GB; Woodard SS; Iyanar K; Case BL; Woerndle R; Dietz JD; Garland DJ; Collins JT; Payne MA; Blinn JR; Pomposiello SI; Hu X; Heron MI; Huang HC; Lee LF
    J Med Chem; 2010 Aug; 53(16):5970-8. PubMed ID: 20672820
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
    Mussari CP; Dodd DS; Sreekantha RK; Pasunoori L; Wan H; Posy SL; Critton D; Ruepp S; Subramanian M; Watson A; Davies P; Schieven GL; Salter-Cid LM; Srivastava R; Tagore DM; Dudhgaonkar S; Poss MA; Carter PH; Dyckman AJ
    ACS Med Chem Lett; 2020 Sep; 11(9):1751-1758. PubMed ID: 32944143
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Medicinal chemistry of P2X receptors: agonists and orthosteric antagonists.
    Lambertucci C; Dal Ben D; Buccioni M; Marucci G; Thomas A; Volpini R
    Curr Med Chem; 2015; 22(7):915-28. PubMed ID: 25515515
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
    Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.